In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...

Experimental drug slashes triglycerides and remnant cholesterol in trial, potentially filling gap for patients with ...

A study led by researchers from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, revealed a new liver- and ...

In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three ...

Statins are the go-to medications for lowering “bad” LDL cholesterol, reducing the risk of cardiovascular disease and ...

Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated ...

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that causes very high triglyceride levels in the body. Tryngolza (olezarsen) was approved in 2024 and is the first and only ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis ...

Tryngolza (olezarsen) is a prescription drug approved to lower triglyceride levels in adults with a certain genetic condition. Tryngolza comes as a liquid solution for injection under the skin.